No Data
Alnylam Pharmaceuticals And Two More Value Stocks On US Exchange Estimated To Be Trading Below Intrinsic Value
BMO Sees BMRN, LEGN, SLN as Attractive M&A Targets
Express News | Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $357
Express News | Alnylam Pharmaceuticals Shares up 1.1% After Canaccord Genuity Raises PT on Stock
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $357
CCORF analyst Whitney Ijem maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and adjusts the target price from $283 to $357.According to TipRanks data, the analyst has a success rate of
Express News | Alnylam Pharmaceuticals Inc : Canaccord Genuity Raises Target Price to $357 From $283
151652693 : There are many theories that do not touch the QE factor that caused the rise and harvest of global finance
151336027 :